The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
Open accessAbstract
BACKGROUND: Somatic mutations in the Janus kinase 2 gene (JAK2) occur in many myeloproliferative neoplasms, but the molecular pathogenesis of myeloproliferative neoplasms with nonmutated JAK2 is obscure, and the diagnosis of these neoplasms remains a challenge. METHODS: We performed exome sequencing of samples obtained from 151 patients with myeloproliferative neoplasms. The mutation status of the gene encoding calreticulin (CALR) was assessed in an additional 1345 hematologic cancers, 1517 other cancers, and 550 controls. We established phylogenetic trees using hematopoietic colonies. We assessed calreticulin subcellular localization using immunofluorescence and flow cytometry. RESULTS: Exome sequencing identified 1498 mutations in 151 patients, with medians of 6.5, 6.5, and 13.0 mutations per patient in samples of polycythemia vera, essential thrombocythemia, and myelofibrosis, respectively. Somatic CALR mutations were found in 70 to 84% of samples of myeloproliferative neoplasms with nonmutated JAK2, in 8% of myelodysplasia samples, in occasional samples of other myeloid cancers, and in none of the other cancers. A total of 148 CALR mutations were identified with 19 distinct variants. Mutations were located in exon 9 and generated a +1 base-pair frameshift, which would result in a mutant protein with a novel C-terminal. Mutant calreticulin was observed in the endoplasmic reticulum without increased cell-surface or Golgi accumulation. Patients with myeloproliferative neoplasms carrying CALR mutations presented with higher platelet counts and lower hemoglobin levels than patients with mutated JAK2. Mutation of CALR was detected in hematopoietic stem and progenitor cells. Clonal analyses showed CALR mutations in the earliest phylogenetic node, a finding consistent with its role as an initiating mutation in some patients. CONCLUSIONS: Somatic mutations in the endoplasmic reticulum chaperone CALR were found in a majority of patients with myeloproliferative neoplasms with nonmutated JAK2. (Funded by the Kay Kendall Leukaemia Fund and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“But many of the most commonly seen mutations in CHIP are also recurrent drivers of AML 64, myelodysplastic syndrome (MDS) 65–67, myeloproliferative neoplasms 68, and certain lymphomas 69,70.”
From Clonal hematopoiesis in human aging and disease (2019) · cites this paper as [68]
In the citing paper
“Calreticulin gene (CALR) mutations frequently occur in Philadelphia chromosome (Ph)-negative myeloproliferative neoplasms (MPNs), including essential thrombocythemia (ET), primary myelofibrosis (PMF), and polycythemia vera (PV) [188–190].”
From Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies (2020) · cites this paper as [188]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
Swerdlow, S. H. (2017) · Medical Entomology and Zoology · Cited by 12,933
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
Baxter, E. J., Scott, L. M., Campbell, P. J., East, C., Fourouclas, N., Swanton, S., Vassiliou, G. S., Bench, A. J., Boyd, E. M., Curtin, N., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)71142-9 · Cited by 3,548
Self-citationA unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
James, C., Ugo, V., Couedic, J. P. L., Staerk, J., Delhommeau, F., Lacout, C., Garçon, L., Raslová, H., Berger, R., Griscelli, A. B., et al. (2005) · Nature · doi:10.1038/nature03546 · Cited by 3,542
A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders
Kralovics, R., Passamonti, F., Buser, A. S., Teo, S.-S., Tiedt, R., Passweg, J. R., Tichelli, A., Cazzola, M., & Skoda, R. C. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051113 · Cited by 3,470
Immunogenic cell death and DAMPs in cancer therapy
Krysko, D. V., Garg, A. D., Kaczmarek, A., Krysko, O., Agostinis, P., & Vandenabeele, P. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3380 · Cited by 3,223
Patterns of somatic mutation in human cancer genomes
Greenman, C. D., Stephens, P., Smith, R., Dalgliesh, G. L., Hunter, C., Bignell, G. R., Davies, H. R., Teague, J. W., Butler, A. P., Stevens, C., et al. (2007) · Nature · doi:10.1038/nature05610 · Cited by 3,062
Self-citationLevine, R. L., Wadleigh, M., Cools, J., Ebert, B. L., Wernig, G., Huntly, B. J. P., Boggon, T. J., Wlodarska, I., Clark, J. J., Moore, S., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.03.023 · Cited by 2,993
Self-citationClinical and biological implications of driver mutations in myelodysplastic syndromes
Papaemmanuil, E., Gerstung, M., Malcovati, L., Tauro, S., Gundem, G., Van Loo, P., Yoon, C. J., Ellis, P., Wedge, D. C., Pellagatti, A., et al. (2013) · Blood · doi:10.1182/blood-2013-08-518886 · Cited by 1,832
Self-citation
Research works printed but not linked: 1
- Chao MP, 2010, Sci Transl Med, 2, 63ra94
Cited by
Sorted by citations
Items 801–900 of 1,002
Treatment of non-cirrhotic, non-tumoural portal vein thrombosis
Llop, E., & Seijó, S. (2016) · Gastroenterología y Hepatología (English Edition) · doi:10.1016/j.gastre.2015.09.001 · Cited by 15
Therapeutic Apheresis for Patients with Cancer
Connelly‐Smith, L. S., & Linenberger, M. L. (2015) · Cancer Control · doi:10.1177/107327481502200109 · Cited by 15
Gugliotta, L., Iurlo, A., Gugliotta, G., Tieghi, A., Specchia, G., Gaïdano, G., Scalzulli, P. R., Rumi, E., Dragani, A., Martinelli, V., et al. (2016) · Leukemia Research · doi:10.1016/j.leukres.2016.04.004 · Cited by 15
Self-citationCurto‐García, N., & Harrison, C. N. (2017) · Future Oncology · doi:10.2217/fon-2017-0298 · Cited by 16
Self-citationPolycythemia vera and essential thrombocythemia: algorithmic approach
Vannucchi, A. M., Guglielmelli, P., & Tefferi, A. (2017) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000402 · Cited by 15
Self-citationJAK2 (and other genes) be nimble with MPN diagnosis, prognosis, and therapy
Ciboddo, M., & Mullally, A. (2018) · Hematology · doi:10.1182/asheducation-2018.1.110 · Cited by 15
Essential thrombocytosis attributed to JAK2-T875N germline mutation
Yoshimitsu, M., Hachiman, M., Uchida, Y., Arima, N., Arai, A., Kamada, Y., Shide, K., Ito, M., Shimoda, K., & Ishitsuka, K. (2019) · International Journal of Hematology · doi:10.1007/s12185-019-02725-8 · Cited by 15
Ruxolitinib-based combinations in the treatment of myelofibrosis: worth looking forward to
Li, Y., Zhu, S., Liu, W., Ming, J., Wang, X., & Hu, X. (2020) · Annals of Hematology · doi:10.1007/s00277-020-04028-z · Cited by 15
Advances and challenges in the management of essential thrombocythemia
Birgegård, G. (2015) · Therapeutic Advances in Hematology · doi:10.1177/2040620715580068 · Cited by 15
Mesa, R. A., & Passamonti, F. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_159322 · Cited by 15
Koschmieder, S., Isfort, S., Schulte, C., Jacobasch, L., Geer, T., Reiser, M., Koenigsmann, M., Heinrich, B., Wehmeyer, J., von der Heyde, E., et al. (2023) · Annals of Hematology · doi:10.1007/s00277-023-05458-1 · Cited by 15
Tumor-suppressive functions of protein lysine methyltransferases
Aziz, N., Hong, Y. H., Kim, H. G., Kim, J. H., & Cho, J. Y. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01117-7 · Cited by 14
Endothelial Damage in JAK2V617F Myeloproliferative Neoplasms with Splanchnic Vein Thrombosis
Moner, B. D., Martínez-Sánchez, J., Garrote, M., Ramos, Á., Ventosa-Capell, H., Moreno‐Castaño, A. B., Nomdedéu, M., Ojeda, A., Escolar, G., García‐Pagán, J. C., et al. (2025) · Thrombosis and Haemostasis · doi:10.1055/a-2498-4849 · Cited by 14
Current Challenges in Stem Cell Transplantation in Myelofibrosis
Kröger, N. M. (2015) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-015-0279-9 · Cited by 14
Calreticulin Mutations in Myeloproliferative Neoplasms: Comparison of Three Diagnostic Methods
Park, J., Sevin, M., Ramla, S., Truffot, A., Verrier, T., Bouchot, D., Courtois, M., Bas, M., Benali, S., Bailly, F., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0141010 · Cited by 14
Kourié, H. R., Ameye, L., Paesmans, M., & Bron, D. (2016) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2016.01.009 · Cited by 14
Daitoku, S., Takenaka, K., Yamauchi, T., Yurino, A., Jinnouchi, F., Nunomura, T., Eto, T., Kamimura, T., Higuchi, M., Harada, N., et al. (2016) · Experimental Hematology · doi:10.1016/j.exphem.2016.05.001 · Cited by 14
Toppaldoddi, K. R., Cacemiro, M. D. C., Bluteau, O., Panneau-Schmaltz, B., Pioch, A., Muller, D., Villeval, J., Raslová, H., Constantinescu, S. N., Plo, I., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0538-z · Cited by 14
Soliman, E. A., El‐Ghlban, S., El-Aziz, S. A., Abdelaleem, A. H., Shamaa, S. S. A., & Abdel-Ghaffar, H. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2020.05.011 · Cited by 14
Applications of next-generation sequencing in hematologic malignancies
Ramkissoon, L. A., & Montgomery, N. D. (2021) · Human Immunology · doi:10.1016/j.humimm.2021.02.006 · Cited by 14
Tillmann, S., Olschok, K., Schröder, S. K., Bütow, M., Baumeister, J., Kalmer, M., Preußger, V. K., Weinbergerová, B., Kricheldorf, K., Mayer, J., et al. (2021) · Cancers · doi:10.3390/cancers13164210 · Cited by 14
Chen, R., Zhang, H., Wu, W., Li, S., Wang, Z., Dai, Z., Liu, Z., Zhang, J., Luo, P., Xia, Z., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.833792 · Cited by 14
Molecular Genetic Biomarkers in Myeloid Malignancies
Matynia, A. P., Szankasi, P., Shen, W., & Kelley, T. W. (2014) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2014-0096-ra · Cited by 15
Splicing factor mutations in AML
Ogawa, S. (2014) · Blood · doi:10.1182/blood-2014-04-566752 · Cited by 14
Allo-SCT for myelofibrosis: reversing the chronic phase in the JAK inhibitor era?
Tamari, R., Mughal, T. I., Rondelli, D., Hasserjian, R. P., Gupta, V. K., Odenike, O. M., Fauble, V. D. S., Finazzi, G., Pane, F., Mascarenhas, J. O., et al. (2015) · Bone Marrow Transplantation · doi:10.1038/bmt.2014.323 · Cited by 14
Harrison, C. N., & Curto‐García, N. (2014) · Hematology · doi:10.1182/asheducation-2014.1.348 · Cited by 14
Self-citationGeyer, J. T., & Orazi, A. (2016) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.12509 · Cited by 14
Managing patients with myelofibrosis and low platelet counts
Al‐Ali, H. K., & Vannucchi, A. M. (2016) · Annals of Hematology · doi:10.1007/s00277-016-2697-8 · Cited by 14
Self-citationCell autonomous expression of CXCL-10 in JAK2V617F-mutated MPN
Schnoeder, T. M., Eberhardt, J., Koehler, M., Bierhoff, H., Weinert, S., Pandey, A. D., Nimmagadda, S. C., Wolleschak, D., Jöhrens, K., Fischer, T., et al. (2017) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-017-2354-1 · Cited by 14
Management of myelofibrosis: JAK inhibition and beyond
Stahl, M. F., & Zeidan, A. M. (2017) · Expert Review of Hematology · doi:10.1080/17474086.2017.1317590 · Cited by 14
Reilly, C. R., Babushok, D. V., Martin, K. A., Spivak, J. L., Streiff, M. B., Bahirwani, R., Mondschein, J. I., Stein, B. L., Moliterno, A. R., & Hexner, E. O. (2017) · American Journal of Hematology · doi:10.1002/ajh.24798 · Cited by 14
Azevedo, A. P., Silva, S., Reichert, A., Lima, F., Júnior, E., & Rueff, J. (2017) · Biomedical Reports · doi:10.3892/br.2017.977 · Cited by 14
Zhou, A. W., Afzal, A., & Oh, S. T. (2017) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-017-0401-2 · Cited by 14
Regulation of Malignant Hematopoiesis by Bone Marrow Microenvironment
Asada, N. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00119 · Cited by 16
Atypical myeloproliferative neoplasm with concurrent BCR-ABL1 fusion and CALR mutation
Liu, C., Hu, R., Du, Z., Abecasis, M., & Wang, C. (2020) · Medicine · doi:10.1097/md.0000000000018811 · Cited by 14
Shide, K., Kameda, T., Kamiunten, A., Ozono, Y., Tahira, Y., Yokomizo‐Nakano, T., Kubota, S., Ono, M., Ikeda, K., Sekine, M., et al. (2020) · Blood · doi:10.1182/blood.2019003358 · Cited by 14
Inano, T., Araki, M., Morishita, S., Imai, M., Kihara, Y., Okuda, M., Yang, Y., Ito, M., Osaga, S., Mano, H., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-97106-9 · Cited by 14
Kirschner, M., Schemionek, M., Schubert, C., Chatain, N., Sontag, S., Isfort, S., Ortiz‐Brüchle, N., Schmitt, K., Krüger, L., Zerres, K., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0123476 · Cited by 14
Angona, A., Álvarez‐Larrán, A., Bellosillo, B., Longarón, R., Camacho, L., Fernández-Rodriguez, M. C., Pairet, S., & Besses, C. (2016) · Leukemia Research · doi:10.1016/j.leukres.2016.06.009 · Cited by 14
The Calreticulin gene and myeloproliferative neoplasms
Clinton, A., & McMullin, M. F. (2016) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2016-203899 · Cited by 14
Another Piece of the Myeloproliferative Neoplasms Puzzle
Levine, R. L. (2013) · New England Journal of Medicine · doi:10.1056/nejme1313643 · Cited by 14
Current Advances in the Diagnosis and Treatment of Major Myeloproliferative Neoplasms
Wang, L., Li, J. Y., Arbitman, L., Zhang, H., Shao, H., Martin, M., Moscinski, L. C., & Song, J. (2025) · Cancers · doi:10.3390/cancers17111834 · Cited by 13
Self-citationClosing the gap: genetic landscape of MPN
Harrison, C. N., & Vannucchi, A. M. (2016) · Blood · doi:10.1182/blood-2015-10-674101 · Cited by 13
Self-citationWang, B., Wen, L., Wang, Z., Chen, S., & Qiu, H. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2021.11.013 · Cited by 13
Iurlo, A., Galli, N., Bucelli, C., Artuso, S., Consonni, D., & Cattaneo, D. (2022) · British Journal of Haematology · doi:10.1111/bjh.18526 · Cited by 13
Enblom‐Larsson, A., Renlund, H., Andréasson, B., Holmberg, H., Liljeholm, M., & Själander, A. (2024) · British Journal of Haematology · doi:10.1111/bjh.19337 · Cited by 13
Özdemir, Z. N., İpek, Y., Patır, P., Ermiş, G., Çiftçiler, R., Özmen, D., Baysal, M., Gürsoy, V., Yıldızhan, E., Güven, S., et al. (2024) · Turkish Journal of Hematology · doi:10.4274/tjh.galenos.2024.2023.0430 · Cited by 13
Maintenance of hematopoietic stem cells by tyrosine-unphosphorylated STAT5 and JAK inhibition
Williams, M., Wang, X., Bastos, H. P., Grondys-Kotarba, G., Johnson, C., Mende, N., Calderbank, E. F., Wantoch, M., Park, H. J., Wu, Q., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024014046 · Cited by 17
Self-citationFedratinib in 2025 and beyond: indications and future applications
Coltoff, A. R., & Mascarenhas, J. O. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024015365 · Cited by 13
JAK2 inhibition mediates clonal selection of RAS pathway mutations in myeloproliferative neoplasms
Maslah, N., Kaci, N., Roux, B., Alexe, G., Marie, R., Pasquer, H., Verger, E., Oliveira, R. D. D., Culeux, C., Mlayah, B., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-60884-1 · Cited by 16
JAK2 V617F Mutation Status of 232 Patients Diagnosed With Chronic Myeloproliferative Neoplasms
Payzin, K. B., Savasoglu, K., Alacacıoğlu, İ., Özdemirkıran, F., Mutlu, B. B., Bener, S., Çallı, A. Ö., Kucukzeybek, B. B., & Aksun, S. (2014) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2014.02.013 · Cited by 13
CALR mutations in Chinese Budd–Chiari syndrome patients
Zhang, P., Ma, H., Min, Q., Zu, M., & Lu, Z. (2016) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000000526 · Cited by 13
Emerging drugs for the treatment of Myelofibrosis
Shreenivas, A. V., & Mascarenhas, J. O. (2018) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2018.1445718 · Cited by 13
Zebrafish for thrombocytopoiesis- and hemostasis-related researches and disorders
Meng, P., Wu, L., Lin, Q., & Zhang, Y. (2020) · Blood Science · doi:10.1097/bs9.0000000000000043 · Cited by 13
Temporal order of mutations influences cancer initiation dynamics
Teimouri, H., & Kolomeisky, A. B. (2021) · Physical Biology · doi:10.1088/1478-3975/ac0b7e · Cited by 14
Kiem, D., Wagner, S. M., Magnes, T., Egle, A., Greil, R., & Melchardt, T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179555 · Cited by 13
New Markers of Disease Progression in Myelofibrosis
Campanelli, R., Massa, M., Rosti, V., & Barosi, G. (2021) · Cancers · doi:10.3390/cancers13215324 · Cited by 13
The Contribution of JAK2 46/1 Haplotype in the Predisposition to Myeloproliferative Neoplasms
Paes, J. F., Silva, G., Tarragô, A. M., & Mourão, L. P. D. S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012582 · Cited by 13
Cattaneo, D., Bucelli, C., Marchetti, A., Lionetti, M., Fermo, E., Bellani, V., Magistris, C. D., Maeda, A., Marella, A., Primignani, M., et al. (2023) · Annals of Hematology · doi:10.1007/s00277-023-05217-2 · Cited by 13
Paz, D. L., Bader, M. S., Nienhold, R., Rai, S., Fonseca, T. A., Stetka, J., Hao-Shen, H., Mild-Schneider, G., Passweg, J. R., & Skoda, R. C. (2023) · HemaSphere · doi:10.1097/hs9.0000000000000885 · Cited by 13
Olschok, K., Altenburg, B., Toledo, M. A. S., Maurer, A., Abels, A., Beier, F., Gezer, D., Isfort, S., Paeschke, K., Brümmendorf, T. H., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1277453 · Cited by 13
Recent Advances towards the Understanding of Secondary Acute Myeloid Leukemia Progression
Auerbach, S., Puka, B., Golla, U., & Chachoua, I. (2024) · Life · doi:10.3390/life14030309 · Cited by 14
Yao, Q.-M., Zhou, J., Gale, R. P., Li, J., Li, L.-D., Li, N., Chen, S.-S., & Ruan, G. (2015) · Hematology · doi:10.1179/1607845415y.0000000009 · Cited by 13
Self-citationEfficacy of ruxolitinib for myelofibrosis
Santos, F. P. S., & Verstovšek, S. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.923404 · Cited by 13
Primary myelofibrosis: current therapeutic options
Campos, P. D. M. (2016) · Revista Brasileira de Hematologia e Hemoterapia · doi:10.1016/j.bjhh.2016.04.003 · Cited by 13
Stengel, A., Kern, W., Haferlach, T., Meggendorfer, M., & Haferlach, C. (2016) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22377 · Cited by 13
Rago, A., Latagliata, R., Montanaro, M., Montefusco, E., Andriani, A., Crescenzi, S. L., Mecarocci, S., Spirito, F., Spadea, A., Recine, U., et al. (2015) · Leukemia Research · doi:10.1016/j.leukres.2015.01.001 · Cited by 13
Self-citationDo we need antiplatelet therapy in thrombocytosis? Contra
Scharf, R. E. (2016) · Hämostaseologie · doi:10.5482/hamo-16-06-0016 · Cited by 13
Modeling myeloproliferative neoplasms: From mutations to mouse models and back again
Morotti, A., Rocca, S., Carrà, G., Saglio, G. N., & Brancaccio, M. (2016) · Blood Reviews · doi:10.1016/j.blre.2016.11.004 · Cited by 13
Calreticulin: a new horizon for the testing and treatment of myeloproliferative neoplasms
Guglielmelli, P., Bartalucci, N., Rotunno, G., & Vannucchi, A. M. (2014) · Expert Review of Hematology · doi:10.1586/17474086.2014.920250 · Cited by 13
Self-citationMelikyan, A. L., Subortseva, I. N., Kovrigina, A. M., Shuvaev, V. A., Морозова, Е. В., Галактионовна, Л. Е., Baykov, V. V., Vinogradova, O., Gritsaev, S. V., Ionova, T., et al. (2024) · Clinical oncohematology · doi:10.21320/2500-2139-2024-17-3-291-334 · Cited by 12
Guy, A., Morange, P., & James, C. (2024) · Blood · doi:10.1182/blood.2024025627 · Cited by 12
CALR mutations are infrequent in WHO-defined refractory anemia with ring sideroblasts
Patnaik, M. M., Belachew, A. A., Finke, C. M., Lasho, T. L., Hanson, C. A., & Tefferi, A. (2014) · Leukemia · doi:10.1038/leu.2014.47 · Cited by 12
Antiplatelet Therapy in the Management of Myeloproliferative Neoplasms
Álvarez‐Larrán, A., & Besses, C. (2014) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-014-0226-1 · Cited by 12
Molecular Mechanism of Mutant CALR–Mediated Transformation
Stanley, R. F., & Steidl, U. U. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0238 · Cited by 12
Synoptic Diagnostics of Myeloproliferative Neoplasms: Morphology and Molecular Genetics
Nann, D., & Fend, F. (2021) · Cancers · doi:10.3390/cancers13143528 · Cited by 12
Majeti, R., Jamieson, C. H. M., Pang, W. W., Jaiswal, S., Leeper, N. J., Wernig, G., & Weissman, I. L. (2022) · Annual Review of Medicine · doi:10.1146/annurev-med-042420-104436 · Cited by 12
Kim, T. Y., Kwag, D., Lee, J., Lee, J., Min, G. J., Park, S., Park, S., Jeon, Y., Yoon, J., Shin, S.-H., et al. (2022) · Cancers · doi:10.3390/cancers14184485 · Cited by 12
Putative Role of Neutrophil Extracellular Trap Formation in Chronic Myeloproliferative Neoplasms
Marković, D. C., Maslovarić, I. S., Kovačić, M. V., Vignjević, S., & Ilić, V. L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054497 · Cited by 12
Effects of calreticulin mutations on cell transformation and immunity
Desikan, H., Kaur, A., Pogozheva, I. D., & Raghavan, M. (2023) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17713 · Cited by 12
Metformin use and risk of myeloproliferative neoplasms: a Danish population–based case-control study
Kristensen, D. T., Øvlisen, A. K., Jakobsen, L. H., Severinsen, M. T., Hannig, L. H., Starklint, J., Hilsøe, M. H., Vallentin, A. P., Brabrand, M., Hasselbalch, H. C., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023012266 · Cited by 12
Two faces of ET: CALR and JAK2
Chao, M. P., & Gotlib, J. R. (2014) · Blood · doi:10.1182/blood-2014-01-547596 · Cited by 12
Wang, J., Hao, J., He, N., Ji, C., & Ma, D. (2016) · Turkish Journal of Hematology · doi:10.4274/tjh.2015.0220 · Cited by 12
Saki, N., Shirzad, R., Rahim, F., & Malehi, A. S. (2017) · Clinical & Translational Oncology · doi:10.1007/s12094-017-1618-1 · Cited by 12
Investigational Janus kinase inhibitors in development for myelofibrosis
Bose, P., Abou Zahr, A., & Verstovsek, S. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1323871 · Cited by 12
Trimouille, A., Houcinat, N., Vuillaume, M., Fergelot, P., Boucher, C., Toutain, J., Caignec, C. L., Vincent, M., Nizon, M., Andrieux, J., et al. (2017) · European Journal of Human Genetics · doi:10.1038/s41431-017-0037-7 · Cited by 12
Cytogenetics and associated mutation profile in patients with acute monocytic leukemia
Xing, S., Wang, B., Gao, Y., Li, M., Wang, T., Sun, Y., Shen, Y., & Chao, H. (2019) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.13030 · Cited by 12
Chapeau, E. A., Mandon, E., Gill, J. W., Romanet, V., Ebel, N., Powajbo, V., Andraos, R., Qian, Z., Kininis, M., Zumstein-Mecker, S., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0221635 · Cited by 12
Mansier, O., Prouzet‐Mauleon, V., Jégou, G., Barroso, K., Raymundo, D. P., Chauveau, A., Dumas, P., Lagarde, V., Turcq, B., Pasquet, J., et al. (2019) · Cancers · doi:10.3390/cancers11121921 · Cited by 13
Management of Myelofibrosis: from Diagnosis to New Target Therapies
Iurlo, A., Cattaneo, D., & Bucelli, C. (2020) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-00734-y · Cited by 12
Calreticulin gene mutations in myeloproliferative neoplasms without Janus kinase 2 mutations
Sun, C., Zhang, S., & Li, J. (2014) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2014.953153 · Cited by 12
Self-citationMalherbe, J. A. J., Fuller, K. A., Mirzai, B., Kavanagh, S., So, C. C., Ip, H., Guo, B. B., Forsyth, C. J., Howman, R., & Erber, W. N. (2016) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2016-203625 · Cited by 12
Sequential evaluation of CALR mutant burden in patients with myeloproliferative neoplasms
Cavalloni, C., Rumi, E., Ferretti, V. V., Pietra, D., Roncoroni, E., Bellini, M., Ciboddo, M., Casetti, I. C., Landini, B., Fugazza, E., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16797 · Cited by 12
Azevedo, A. P., Silva, S., de Lima, J. P., Reichert, A., Lima, F., Júnior, E., & Rueff, J. (2017) · Oncology Letters · doi:10.3892/ol.2017.6065 · Cited by 12
Chiang, Y., Chang, Y., Lin, H., Huang, L., Cheng, C., Wang, W., Cheng, H.-I., Su, N.-W., Chen, C. G., Lin, J., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.19211 · Cited by 12
Dynamics of mutations in patients with essential thrombocythemia treated with imetelstat
Leibundgut, E. O., Haubitz, M., Burington, B. E., Ottmann, O. G., Spitzer, G., Odenike, O. M., McDevitt, M. A., Röth, A., Snyder, D., & Baerlocher, G. M. (2020) · Haematologica · doi:10.3324/haematol.2020.252817 · Cited by 12
CALR-ETdb, the database of calreticulin variants diversity in essential thrombocythemia
Jahrani, N. E., Cretin, G., & de Brevern, A. G. (2021) · Platelets · doi:10.1080/09537104.2020.1869712 · Cited by 11
Hernández-Verdín, I., Akdemir, K. C., Ramazzotti, D., Caravagna, G., Labrèche, K., Mokhtari, K., Hoang‐Xuan, K., Peyre, M., Bielle, F., Touat, M., et al. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00331-2 · Cited by 12
Novel strategies targeting mutant calreticulin in essential thrombocythemia and myelofibrosis
Salzman, G., & Mullally, A. (2025) · Blood · doi:10.1182/blood.2025028642 · Cited by 11
Safety considerations when treating myelofibrosis
O’Sullivan, J. M., McLornan, D. P., & Harrison, C. N. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1185414 · Cited by 11
Self-citation
Metadata
- Authors
- Nangalia, J., Massie, C. E., Baxter, E. J., Nice, F. L., Gundem, G., Wedge, D. C., Avezov, E., Li, J., Kollmann, K., Kent, D. G., Aziz, A., Godfrey, A. L., Hinton, J., Martincorena, I., Van Loo, P., Jones, A. V., Guglielmelli, P., Tarpey, P., Harding, H. P., Fitzpatrick, J. D., Goudie, C. T., Ortmann, C. A., Loughran, S. J., Raine, K., Jones, D. R., Butler, A. P., Teague, J. W., O'Meara, S., McLaren, S., Bianchi, M., Silber, Y., Dimitropoulou, D., Bloxham, D., Mudie, L., Maddison, M., Robinson, B., Keohane, C., Maclean, C., Hill, K., Orchard, K., Tauro, S., Du, M.-Q., Greaves, M., Bowen, D., Huntly, B. J. P., Harrison, C. N., Cross, N. C. P., Ron, D., Vannucchi, A. M., Papaemmanuil, E., Campbell, P. J., & Green, A. R.
- ORCID
- Nangalia, J.
- Massie, C.E.
- Baxter, E.J.
- Nice, F.L.
- Gundem, G.
- Wedge, D.C.
- Avezov, E.
- Kollmann, K.
- Kent, D.G.
- Godfrey, A.L.
- Hinton, J.
- Martincorena, I.
- Jones, A.V.
- Guglielmelli, P.
- Tarpey, P.
- Harding, H.P.
- Fitzpatrick, J.D.
- Loughran, S.J.
- Raine, K.
- Jones, D.R.
- Teague, J.W.
- McLaren, S.
- Hill, K.
- Orchard, K.
- Du, M.-Q.
- Greaves, M.
- Bowen, D.
- Huntly, B.J.P.
- Harrison, C.N.
- Cross, N.C.P.
- Ron, D.
- Vannucchi, A.M.
- Papaemmanuil, E.
- Campbell, P.J.
- Green, A.R.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-12-19
- Volume
- 369
- Issue
- 25
- Pages
- 2391-2405
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3966280
- OpenAlex
- W2138709799
- Cited by
- 1,756
- References
- 40
- Citations by year
- 2026: 64 · 2025: 59 · 2024: 72 · 2023: 90 · 2022: 112 · 2021: 133 · 2020: 125 · 2019: 124 · 2018: 130 · 2017: 181 · 2016: 208 · 2015: 239 · 2014: 208 · 2013: 7
- FWCI
- 108.50
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- University of Salford Institutional Repository (University of Salford) (submittedVersion, cc-by)
- Discovery Research Portal (University of Dundee) (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- Florence Research (University of Florence) (submittedVersion)
- Lirias (KU Leuven) (submittedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Funders
- Leukemia and Lymphoma Society
- Leukemia and Lymphoma Research
- University of Salford Manchester
- Wellcome Trust (079249, 100140, 093867, 084812)
- University Hospital Southampton NHS Foundation Trust
- Cancer Research UK (12526, 12765, 15488)
- National Institute for Health and Care Research (NF-SI-0512-10079)
- Kay Kendall Leukaemia Fund
- University of Southampton
- KU Leuven
- Università degli Studi di Firenze
- Associazione Italiana per la Ricerca sul Cancro
- Vlaamse regering
- Canadian Institutes of Health Research
- Medical Research Council
- Cambridge Institute for Medical Research, University of Cambridge
- NIHR Cambridge Biomedical Research Centre
- Dipartimento di Medicina Sperimentale e Clinica, Università degli Studi di Firenze
- Topics
- Health Sciences › Medicine › Hematology › Myeloproliferative Neoplasms: Diagnosis and Treatment
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Keywords
- calreticulin, CALR mutation, myeloproliferative neoplasms, polycythemia vera, essential thrombocythemia, myelofibrosis, myelodysplastic syndrome, endoplasmic reticulum chaperone, clonal evolution, hematopoietic stem and progenitor cells, somatic mutations
- MeSH terms
- Amino Acid Sequence, Bone Marrow Diseases, Exons, Humans, Leukemia, Myeloid, Molecular Sequence Data, Mutation, Myelodysplastic Syndromes, Neoplasms, Thrombocythemia, Essential, Polymerase Chain Reaction, Sequence Analysis, DNA, Calreticulin, Janus Kinase 2, Primary Myelofibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review